Treating Older AML Patients and Managing Unique Toxicities

Drs Gail Roboz and Courtney DiNardo discuss methods of treating older patients with acute myeloid leukemia and managing unique toxicities.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/964537). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Acute Myeloid Leukemia https://emedicine.medscape.com/article/197802-overview

Cytarabine https://reference.medscape.com/drug/cytosar-u-depocyt-cytarabine-342089

Mylotarg (gemtuzumab ozogamicin) https://reference.medscape.com/drug/mylotarg-gemtuzumab-1000186

A Phase 3 Trial of Azacitidine Versus a Semi-Intensive Fludarabine and Cytarabine Schedule in Older Patients With Untreated Acute Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/33626197/

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia https://www.nejm.org/doi/full/10.1056/NEJMoa2012971

Ferrara Criteria https://decisionpoint.medscape.com/oncology/viewarticle/928810

Hydrea https://reference.medscape.com/drug/droxia-siklos-hydroxyurea-342100

Mucositis https://emedicine.medscape.com/article/1079570-overview

Azacytidine https://reference.medscape.com/drug/onureg-vidaza-azacitidine-342263

Decitabine https://reference.medscape.com/drug/dacogen-decitabine-342091

Venetoclax https://reference.medscape.com/drug/venclexta-venetoclax-1000078

Hydroxycarbamide in Combination With Azacitidine or Decitabine Is Antagonistic on DNA Methylation Inhibition https://pubmed.ncbi.nlm.nih.gov/17686055/